SABCS 2022 Conference Coverage
Playback speed
10 seconds
SABCS 2022 Updated Survival Results of the Randomized Phase 3 Study DESTINY-Breast03: T-DXd vs. Trastuzumab Emtansine in Patients With HER2+ mBC
By
SABCS 2022 Conference Coverage
FEATURING
Sara A. Hurvitz
By
SABCS 2022 Conference Coverage
FEATURING
Sara A. Hurvitz
251 views
December 14, 2022
Login to view comments.
Click here to Login
Videos